Albuterol efficacy in bronchitis
Pro Research Analysisby 
Searched over 200M research papers
Albuterol Efficacy in Acute Bronchitis: Symptom Relief and Cough Reduction
Several studies have examined the use of albuterol in treating acute bronchitis, particularly focusing on its ability to relieve cough and improve patient well-being. Research comparing albuterol to antibiotics like erythromycin found that patients treated with albuterol were less likely to be coughing after 7 days (41% vs 88%), regardless of smoking status or sputum characteristics. There were also trends toward earlier improvement in cough and overall well-being in the albuterol group, though no differences were seen in time to return to work or normal activities. Side effects were minor and similar between groups, suggesting that oral albuterol may be more effective than antibiotics for symptom relief in acute bronchitis .
Another study using albuterol delivered by metered-dose inhaler (MDI) confirmed these findings, showing that patients with acute bronchitis were less likely to be coughing after 7 days when treated with albuterol compared to placebo (61% vs 91%). This benefit was consistent regardless of smoking status or concurrent antibiotic use, indicating that albuterol can help reduce cough duration in acute bronchitis .
Albuterol in Bronchiolitis: Limited Efficacy in Infants
In contrast to its effects in acute bronchitis, multiple studies have found that albuterol does not significantly improve outcomes in infants with bronchiolitis. Randomized, double-blind, placebo-controlled trials in infants with their first episode of wheezing due to bronchiolitis showed no significant differences in respiratory rate, symptom score, heart rate (except for a mild increase with oral albuterol), or oxygen saturation between albuterol and placebo groups. Hospital admission rates and need for additional treatment were also similar, indicating that albuterol did not alter the course of bronchiolitis in these infants 1310.
A further study using oral albuterol in infants with mild-to-moderate acute viral bronchiolitis found no significant differences in time to resolution of illness or secondary outcomes such as feeding, sleeping, or cough resolution compared to placebo. Health care revisit and admission rates were also similar, leading to the conclusion that oral albuterol is not recommended for widespread use in this patient group .
Nebulized Albuterol: Mixed Results in Bronchiolitis
Some research has suggested that nebulized albuterol may provide modest improvements in clinical scores, respiratory rate, and oxygen saturation in infants with bronchiolitis, but these effects are generally small and not consistently observed across studies. For example, one trial found that nebulized albuterol led to greater improvement in accessory muscle use and oxygen saturation compared to placebo, with a slight increase in heart rate but no other significant side effects. However, the response was similar in infants younger and older than 6 months, and the overall clinical impact was limited .
Other studies have shown that adding ipratropium bromide to nebulized albuterol does not provide additional benefit over albuterol alone in bronchiolitis, with both treatments resulting in similar improvements and no significant differences in hospitalization rates or side effects .
Data Quality and Meta-Analysis Considerations
Recent analysis of meta-analyses on albuterol use in bronchiolitis has identified data miscalculations and errors in previous reviews. After correcting these errors, the direction of effect for albuterol switched to a slight, non-significant decrease in oxygen saturation, aligning with clinical observations that albuterol may transiently reduce oxygen saturation in infants with bronchiolitis .
Conclusion
Albuterol appears to be effective in reducing cough and improving symptoms in adults with acute bronchitis, regardless of smoking status or antibiotic use 25. However, in infants with bronchiolitis, both oral and nebulized albuterol generally do not provide significant clinical benefit and are not recommended for routine use 13710. Some modest improvements may be seen with nebulized albuterol, but these are not consistent or clinically significant across studies 69. Data quality issues in previous meta-analyses further support the conclusion that albuterol is not effective for bronchiolitis in infants .
Sources and full results
Most relevant research papers on this topic